No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Clearmind Medicine Secures Patent For Psychedelic Combination Therapy In Mexico
SciSparc And Clearmind Announces Mexican Patent Application For MDMA And N-Acylethanolamines Therapy Combination
Clearmind Medicine | 20-F: FY2024 Annual Report
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
Press Release: Clearmind Medicine Announces Shareholders Meeting Results
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?